evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

149 questions · 159 findings · 18 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 21 · 13.2%GRADE not reported 8 · 5%Very low 33 · 20.8%Low 62 · 39%Moderate 29 · 18.2%High 6 · 3.8%

Perineural vs intravenous dexamethasone

Incidence of serious adverse events (we used the NIH definition of adverse events. A serious event includes death, a life‐threatening event that requires hospitalization or prolonged hospitalization, disability or congenital anomaly) · peripheral nerve block

The review found no eligible studies for this question.

1 finding from 1 review

Perineural vs intravenous dexamethasone

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · peripheral nerve block
3 findings from 1 review

Lower vs higher cumulative dose dexamethasone regimen

Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia

Lower showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks PMA compared with higher cumulative dose dexamethasone regimen (low certainty).

1 finding from 1 review

Individual tailored vs continuous tapered dexamethasone regimen

Death or cerebral palsy at 1 to 3 years · preterm infants at risk for bronchopulmonary dysplasia

Individual tailored showed no clear difference in death or cerebral palsy at 1 to 3 years compared with continuous tapered dexamethasone regimen (moderate certainty).

1 finding from 1 review

Individual tailored vs continuous tapered dexamethasone regimen

Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia

Individual tailored showed no clear difference in death or abnormal neurodevelopmental outcome (various definitions) compared with continuous tapered dexamethasone regimen (low certainty).

1 finding from 1 review

Lower vs higher cumulative dose dexamethasone regimen

Death or cerebral palsy at 1 to 3 years · preterm infants at risk for bronchopulmonary dysplasia

Lower showed no clear difference in death or cerebral palsy at 1 to 3 years compared with higher cumulative dose dexamethasone regimen (low certainty).

1 finding from 1 review

Lower vs higher cumulative dose dexamethasone regimen

Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia

It is very uncertain whether lower changes death or abnormal neurodevelopmental outcome (various definitions)… compared with higher cumulative dose dexamethasone regimen (very low certainty).

1 finding from 1 review

Later vs earlier initiation of dexamethasone therapy

Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia

Later showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks' PMA compared with earlier initiation of dexamethasone therapy (low certainty).

1 finding from 1 review

Later vs earlier initiation of dexamethasone therapy

Death or cerebral palsy at 1 to 3 years · preterm infants at risk for bronchopulmonary dysplasia

Later showed no clear difference in death or cerebral palsy at 1 to 3 years compared with earlier initiation of dexamethasone therapy (low certainty).

1 finding from 1 review

Later vs earlier initiation of dexamethasone therapy

Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia

Later showed no clear difference in death or abnormal neurodevelopmental outcome (various definitions) compared with earlier initiation of dexamethasone therapy (low certainty).

1 finding from 1 review

Pulse vs continuous dexamethasone therapy

Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia

Pulse may leads to higher death or bronchopulmonary dysplasia at 36 weeks' PMA compared with continuous dexamethasone therapy (low certainty).

1 finding from 1 review

Pulse vs continuous dexamethasone therapy

Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia

It is very uncertain whether pulse changes death or abnormal neurodevelopmental outcome (various definitions) compared with continuous dexamethasone therapy (very low certainty).

1 finding from 1 review

Individual tailored vs continuous tapered dexamethasone regimen

Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia

Individual tailored showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks PMA compared with continuous tapered dexamethasone regimen (low certainty).

1 finding from 1 review